£50.0M
NRG Therapeutics raises £50m in Series B funding to advance mitochondrial drugs into clinical trials
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
NT
NRG Therapeutics
NRG Therapeutics develops mitochondrial-targeted treatments for neurodegenerative conditions.
Stevenage, UK
£50.0MTotal raised
Stevenage-based biotechnology company developing small molecule therapeutics to target mitochondrial dysfunction in neurodegenerative diseases.
Categories
Founders
NM
Neil Miller
CEO
RR
Richard Rutter
CSO
GH
Grant Hawthorn
COO